Insulet Corp (NASDAQ: PODD) President and Chief Executive Officer Ashley McEvoy bought 4,300 shares of the company's common stock on February 20, 2026, according to a Form 4 filed with the U.S. Securities and Exchange Commission.
The purchase was executed at a weighted average price of $239.35 per share, producing a total transaction value of approximately $1.03 million. Reported execution prices for the individual lots ranged from $238.55 to $241.56. After the acquisition, McEvoy directly holds 13,916 shares of Insulet.
The insider activity took place while Insulet's stock was trading close to its 52-week low of $230.05 and roughly 15% lower year-to-date, based on the filing and market commentary included in the filing disclosure.
Market intelligence from InvestingPro flagged the shares as appearing undervalued at current levels based on the platform's Fair Value assessment. The service also lists 14 additional ProTips for PODD, which include commentary on analyst earnings-revision activity and an assessment of the company’s financial health score.
Separately, Insulet released its fourth-quarter 2025 financial results, reporting revenue of $784 million. The company described that figure as a 29% increase in constant currency and noted that it exceeded both Oppenheimer’s estimate of $768 million and the consensus expectation of $769 million.
Canaccord Genuity’s reporting of Insulet revenue recorded a close figure of $783.8 million, representing a 31.2% year-over-year increase in constant currency and topping Canaccord’s own forecast of $772.5 million.
Despite stronger-than-expected top-line performance, Insulet posted earnings per share of $1.44 for the quarter, which was a slight miss relative to analyst forecasts.
Analyst responses to the results and competitive dynamics in the insulin pump market have been mixed. Bernstein trimmed its price target to $330, citing concerns over competition. Oppenheimer lowered its target to $300 while maintaining an Outperform rating. Canaccord Genuity reduced its target to $435 but kept a Buy recommendation. BTIG reiterated a Buy rating with a $380 price target, pointing to the strength of fourth-quarter results.
The combination of an insider purchase, revenue outperformance, an EPS shortfall and diverging analyst target adjustments underpins the current market narrative around Insulet. Investors and analysts are weighing top-line momentum against competitive pressures and margin dynamics as represented in recent forecasts and ratings.